Humacyte (HUMA) Q4 2024 earnings summary

Executive summary

• Achieved FDA approval and commercial launch of SYMVESS/Symvess for extremity vascular trauma after over 20 years of R&D, with first shipments to Level 1 trauma centers and 34 hospitals initiating VAC approval processes.

• Strong early market response with three hospitals already approving SYMVESS and positive feedback from surgeons.

• Published budget impact model shows SYMVESS/Symvess reduces costs by avoiding infections and amputations compared to alternatives.

• Positive Phase 3 results for ATEV in dialysis access; IND filing planned for small-diameter ATEV in CABG, supported by preclinical data.

• New U.S. patent issued for SYMVESS/Symvess manufacturing, extending protection into 2040.

Financial highlights

• No revenue reported for Q4 or full year 2024, but commercial revenues began in recent weeks with the launch.

• R&D expenses were $20.7M in Q4 2024 (down from $22.9M in Q3 2024), and $88.6M for the year (up from $76.6M in 2023).

• Net loss was $20.9M for Q4 2024 (down from $39.2M in Q3 2024) and $148.7M for the year (up from $110.8M in 2023), mainly due to non-cash remeasurement of contingent earn-out liability.

• Cash, cash equivalents, and restricted cash totaled $95.3M at year-end 2024; $46.6M raised in March 2025 public offering, with potential for $7.1M more.

• Net cash provided in 2024 was $14.5M, compared to $69M used in 2023, mainly due to equity offerings and funding arrangements.

Outlook and guidance

• Majority of 2024 sales expected in the second half due to VAC process timelines; analyst consensus for 2024 sales is $7M–$13M.

• IND filing for small-diameter ATEV in CABG planned for 2025; supplemental BLA for dialysis access indication targeted for H2 2026, pending interim trial results.

• R&D expenses expected to decrease in 2025 as trauma and V007 trials wind down and manufacturing costs shift to cost of sales.

• NTAP reimbursement for SYMVESS/Symvess could begin October 1, 2025, if CMS application is successful.